RS104004A - Calcitonin gene related peptide receptor antagonists - Google Patents
Calcitonin gene related peptide receptor antagonistsInfo
- Publication number
- RS104004A RS104004A YU104004A YUP104004A RS104004A RS 104004 A RS104004 A RS 104004A YU 104004 A YU104004 A YU 104004A YU P104004 A YUP104004 A YU P104004A RS 104004 A RS104004 A RS 104004A
- Authority
- RS
- Serbia
- Prior art keywords
- related peptide
- treatment
- calcitonin gene
- receptor antagonists
- peptide receptor
- Prior art date
Links
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 3
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2807—Headache; Migraine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
Abstract
Sadašnji pronalazak se odnosi na jedinjenja Formule (I) kao antagoniste receptora kalcitonin genom određenog peptida ("CGRP receptori"), farmaceutske sastave koji ih sadrže, postupke za njihovu identifikaciju, postupke za lečenje njihovim korišćenjem i njihovu upotrebu u terapiji neurogene vazodilatacije, neurogene inflamacije, migrene i drugih vrsta glavobolja, opekotina, cirkulatornog šoka, crvenila usled menopauze, inflamatornih oboljenja disajnih puteva, kao što su astma i hronična opstruktivna bolest pluća (HOBP), i ostala stanja koja se mogu lečiti antagonizovanjem CGRP receptora.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38613802P | 2002-06-05 | 2002-06-05 | |
US38861702P | 2002-06-13 | 2002-06-13 | |
US38987002P | 2002-06-19 | 2002-06-19 | |
US39320002P | 2002-07-01 | 2002-07-01 | |
US41353402P | 2002-09-25 | 2002-09-25 | |
PCT/US2003/016576 WO2003104236A1 (en) | 2002-06-01 | 2003-05-27 | Calcitonin gene related peptide receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
RS104004A true RS104004A (en) | 2006-10-27 |
RS52552B RS52552B (sr) | 2013-04-30 |
Family
ID=29741144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU104004A RS52552B (sr) | 2002-06-05 | 2003-05-27 | Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom |
Country Status (24)
Country | Link |
---|---|
US (2) | US20040063735A1 (sr) |
EP (1) | EP1539766B1 (sr) |
JP (1) | JP4490809B2 (sr) |
KR (2) | KR20120004541A (sr) |
CN (1) | CN100558728C (sr) |
AU (1) | AU2003237255B8 (sr) |
BR (1) | BRPI0311812B8 (sr) |
CA (1) | CA2487976C (sr) |
CY (1) | CY1118764T1 (sr) |
DK (1) | DK1539766T3 (sr) |
ES (1) | ES2616539T3 (sr) |
GE (1) | GEP20074231B (sr) |
HR (1) | HRP20041147A2 (sr) |
HU (1) | HUE032132T2 (sr) |
IS (1) | IS7583A (sr) |
LT (1) | LT1539766T (sr) |
MX (1) | MXPA04011960A (sr) |
NO (1) | NO332691B1 (sr) |
NZ (1) | NZ537315A (sr) |
PL (1) | PL374017A1 (sr) |
PT (1) | PT1539766T (sr) |
RS (1) | RS52552B (sr) |
TW (1) | TWI308151B (sr) |
WO (1) | WO2003104236A1 (sr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
KR100661118B1 (ko) * | 2003-11-12 | 2006-12-26 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
US7569578B2 (en) * | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
EP1689493A4 (en) * | 2003-12-05 | 2008-04-23 | Bristol Myers Squibb Co | ANTAGONISTS OF THE CALCITONIN GENE RELATED PEPTIDE RECEPTOR |
EP1695961A4 (en) * | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
EP1722792A1 (de) * | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
JP2007529513A (ja) * | 2004-03-17 | 2007-10-25 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
BRPI0509069B8 (pt) | 2004-03-23 | 2021-05-25 | Pfizer Prod Inc | compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018795A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018794A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7547694B2 (en) * | 2004-04-15 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
CA2580020A1 (en) * | 2004-09-09 | 2006-03-23 | Ian M. Bell | Aryl spirolactam cgrp receptor antagonists |
US7696192B2 (en) * | 2004-09-09 | 2010-04-13 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirolactam CGRP receptor antagonists |
CA2579850A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Tricyclic anilide spirohydantoin cgrp receptor antagonists |
EP1799672B1 (en) * | 2004-10-07 | 2013-01-02 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
CA2583536A1 (en) * | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
EP1802372B1 (en) * | 2004-10-14 | 2011-05-04 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
EP1804919B1 (en) * | 2004-10-22 | 2011-03-30 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
RS20080139A (en) | 2005-09-22 | 2009-05-06 | Pfizer Products Inc., | Imidazole coumpounds for the treatment of neurological disorders |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
JP5123197B2 (ja) | 2005-11-14 | 2013-01-16 | ライナット ニューロサイエンス コーポレイション | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法 |
WO2007100670A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
WO2007146349A2 (en) * | 2006-06-13 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Cgrp receptor antagonists |
US8163737B2 (en) | 2006-06-13 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US7834000B2 (en) | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
CN101553231A (zh) * | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
US8067447B2 (en) * | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AU2007332898A1 (en) | 2006-12-08 | 2008-06-19 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
US8026365B2 (en) | 2007-05-25 | 2011-09-27 | Hoffman-La Roche Inc. | 4,4-disubstituted piperidine derivatives |
NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
EP2470207A1 (en) | 2009-08-28 | 2012-07-04 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
EP2709662B1 (en) | 2011-05-20 | 2019-07-31 | AlderBio Holdings LLC | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
CN103702685B (zh) | 2011-05-20 | 2017-12-15 | 奥尔德生物控股有限责任公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途 |
PL2710039T3 (pl) | 2011-05-20 | 2019-07-31 | Alderbio Holdings Llc | Kompozycje przeciwko CGRP i ich zastosowanie |
CN111973740A (zh) | 2014-03-21 | 2020-11-24 | 泰华制药国际有限公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
SG10201913032TA (en) | 2016-09-23 | 2020-02-27 | Teva Pharmaceuticals Int Gmbh | Treating refractory migraine |
EP3366286A1 (en) | 2017-02-22 | 2018-08-29 | Johannes Keller | Compounds for treating sepsis |
WO2019112024A1 (ja) * | 2017-12-08 | 2019-06-13 | キッセイ薬品工業株式会社 | ピロリジン化合物 |
JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
CA3134550A1 (en) | 2019-04-11 | 2020-10-15 | R.P. Scherer Technologies, Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
CN117624191A (zh) * | 2022-08-30 | 2024-03-01 | 熙源安健医药(上海)有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2168512C2 (ru) | 1992-12-11 | 2001-06-10 | Мерк Энд Ко., Инк. | Спиропиперидины, способы их получения (варианты) |
WO1996016981A2 (en) * | 1994-12-02 | 1996-06-06 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
WO1997009046A1 (en) | 1995-09-05 | 1997-03-13 | Smithkline Beecham Corporation | Compounds and methods |
US5869489A (en) * | 1996-03-25 | 1999-02-09 | Merck & Co., Inc. | Trypthophan ureas as neurokinnin antagonists |
WO1997042951A1 (en) * | 1996-05-16 | 1997-11-20 | Board Of Regents, The University Of Texas System | Methods of identifying modulators of perivascular sensory nerve ca2+ receptors |
EP0934068A1 (en) | 1996-09-09 | 1999-08-11 | Smithkline Beecham Corporation | Compounds and methods |
CZ82399A3 (cs) | 1996-09-10 | 1999-06-16 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem |
US6025372A (en) * | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6063796A (en) * | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
US20030069231A1 (en) * | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
CA2327695A1 (en) | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
JP2002525371A (ja) | 1998-09-30 | 2002-08-13 | メルク シャープ エンド ドーム リミテッド | Cgrpリガンドとしてのベンゾイミダゾリニルピペリジン |
DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6313097B1 (en) * | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
AU7556800A (en) | 1999-10-07 | 2001-05-10 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19963868A1 (de) * | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CN1458922A (zh) * | 2000-09-14 | 2003-11-26 | 东丽株式会社 | 尿素衍生物及以其作为有效成分的粘连分子阻断剂 |
US20030181462A1 (en) * | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
EP1438325B1 (en) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
US6900317B2 (en) * | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
US7026312B2 (en) * | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US20040076587A1 (en) * | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20040248816A1 (en) * | 2003-04-01 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Treatment of migraine |
JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
US20050032783A1 (en) * | 2003-07-07 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
US7569578B2 (en) * | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
EP1722792A1 (de) * | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018796A1 (de) * | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US20050233980A1 (en) * | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
US7696195B2 (en) * | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004027912A1 (de) * | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituierte Cyclopenten-Verbindungen |
US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) * | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
-
2003
- 2003-05-27 CA CA2487976A patent/CA2487976C/en not_active Expired - Lifetime
- 2003-05-27 WO PCT/US2003/016576 patent/WO2003104236A1/en active Application Filing
- 2003-05-27 HU HUE03736721A patent/HUE032132T2/en unknown
- 2003-05-27 NZ NZ537315A patent/NZ537315A/en not_active IP Right Cessation
- 2003-05-27 KR KR1020117028478A patent/KR20120004541A/ko not_active Application Discontinuation
- 2003-05-27 MX MXPA04011960A patent/MXPA04011960A/es active IP Right Grant
- 2003-05-27 US US10/445,523 patent/US20040063735A1/en not_active Abandoned
- 2003-05-27 PT PT37367216T patent/PT1539766T/pt unknown
- 2003-05-27 DK DK03736721.6T patent/DK1539766T3/en active
- 2003-05-27 AU AU2003237255A patent/AU2003237255B8/en not_active Expired
- 2003-05-27 LT LTEP03736721.6T patent/LT1539766T/lt unknown
- 2003-05-27 PL PL03374017A patent/PL374017A1/xx not_active Application Discontinuation
- 2003-05-27 ES ES03736721.6T patent/ES2616539T3/es not_active Expired - Lifetime
- 2003-05-27 KR KR10-2004-7019744A patent/KR20050008790A/ko active Application Filing
- 2003-05-27 RS YU104004A patent/RS52552B/sr unknown
- 2003-05-27 EP EP03736721.6A patent/EP1539766B1/en not_active Expired - Lifetime
- 2003-05-27 JP JP2004511306A patent/JP4490809B2/ja not_active Expired - Lifetime
- 2003-05-27 BR BRPI0311812A patent/BRPI0311812B8/pt active IP Right Grant
- 2003-05-27 GE GEAP8575A patent/GEP20074231B/en unknown
- 2003-05-27 CN CNB038184753A patent/CN100558728C/zh not_active Expired - Lifetime
- 2003-06-03 TW TW092115067A patent/TWI308151B/zh not_active IP Right Cessation
-
2004
- 2004-11-29 NO NO20045219A patent/NO332691B1/no not_active IP Right Cessation
- 2004-12-01 HR HR20041147A patent/HRP20041147A2/hr not_active Application Discontinuation
- 2004-12-03 IS IS7583A patent/IS7583A/is unknown
-
2006
- 2006-12-19 US US11/641,974 patent/US20070148093A1/en not_active Abandoned
-
2017
- 2017-03-20 CY CY20171100344T patent/CY1118764T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS104004A (en) | Calcitonin gene related peptide receptor antagonists | |
WO2005056550A3 (en) | Heterocyclic anti-migraine agents | |
RS20060382A (en) | Calcitonin gene related peptide receptor antagonists | |
TW200628470A (en) | Constrained compounds as CGRP-receptor antagonists | |
BRPI0509341A (pt) | anatagonistas de cgrp hetorocìclicos para o tratamento de enxaqueca | |
TN2012000139A1 (en) | Cgrp receptor antagonists | |
WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
WO2007130860A3 (en) | Constrained compounds as cgrp-receptor antagonists | |
EP2582432B1 (en) | Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections | |
US20140228410A1 (en) | P38map kinase inhibitors | |
RU2007146669A (ru) | Пролекарства антагонистов a2b рецептора аденозина | |
WO2010018109A3 (en) | Substituted aminotetralines | |
SE0200356D0 (sv) | Novel use | |
JP2012504590A (ja) | p38MAPキナーゼ阻害剤 | |
EA200970302A1 (ru) | Тиофенпиразолопиримидиновые соединения | |
NO20065757L (no) | Purinderivater | |
NO20092567L (no) | Acetylendenvater og deres anvendelse til binding og avbilding av amyloidplakker | |
ATE517903T1 (de) | Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten. | |
WO2007131020A3 (en) | Constrained compounds as cgrp-receptor antagonists | |
US6342498B1 (en) | Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists | |
TW200825064A (en) | Novel substituted piperidyl-propane-thiols | |
TW440565B (en) | Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases | |
HRP20060236A2 (en) | Calcitonin gene related peptide receptor antagonists | |
TH65848B (th) | แอนตะกอนิสต์ของรีเซฟเตอร์สำหรับแคลซิโทนินรีเลตเปปไทด์ | |
KR20120106824A (ko) | [4[4?(5?아미노메틸?2?플루오로-페닐)?피페리딘?1?일]?(1h?피롤로?피리딘?일)?메탄온들의 전구약물들 및 이들의 합성 |